DocumentRX-8110
Issued
Read4 min

Sone-Ve receives FDA priority review for advanced gastric cancer

FDA set a Q2 2027 action date for Sone-Ve after Priority Review. The filing rests on a 10.6-month overall-survival result, while central PFS review missed significance.

TAG T-8353 · 701 words on the filing

AstraZeneca’s Sone-Ve Gains FDA Priority Review in Gastric Cancer - Securities.io
AstraZeneca’s Sone-Ve Gains FDA Priority Review in Gastric Cancer - Securities.ioDmitrySidorov / pixabay

Summary of findings

  • FDA accepted the Sone-Ve BLA and granted Priority Review on 19 November 2026, with an action date anticipated in Q2 2027.
  • CLARITY-Gastric01 showed median overall survival of 10.6 months versus 6.4 months, with a hazard ratio of 0.58 and p=0.000004.
  • Blinded independent central review found no statistically significant progression-free survival benefit in the overall population (p=0.053193).
  • The proposed biomarker threshold covers CLDN18.2 expression in at least 25% of tumour cells, a group AstraZeneca says represents about 60% of gastric and GEJ cancers.
  • AstraZeneca’s KYM licence included a US$63 million upfront payment, up to $1.1 billion in milestones and tiered royalties up to low double digits.

By Olivia Hart

AstraZeneca said on 19 November 2026 that the FDA had accepted its Biologics License Application for sonesitatug vedotin (Sone-Ve), granted Priority Review and anticipated an action date in the second quarter of 2027.

The application covers second- and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma (EAC). The proposed population includes patients whose tumours express Claudin 18.2 (CLDN18.2) on at least 25% of tumour cells at any staining intensity.

What does Priority Review change for developers?

For portfolio and regulatory teams, Priority Review changes the timetable, not the evidentiary bar. The FDA aims to act within six months, compared with 10 months under standard review. The designation concentrates agency attention and resources on medicines that could significantly improve the treatment of serious conditions, but leaves the approval standard and evidence requirements unchanged.

AstraZeneca estimates that 60% of gastric and GEJ cancers meet the proposed CLDN18.2 expression threshold. About 7,500 patients in the United States receive treatment each year in the second- and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric or GEJ cancers.

The evidence behind the filing

CLARITY-Gastric01 results, released on 25 October 2026, underpin the application. A planned interim analysis used data cut off on 31 May 2026 and produced four central findings:

  • Sone-Ve delivered median overall survival of 10.6 months in the second- and later-line population, against 6.4 months with investigator’s choice of therapy. The hazard ratio was 0.58 (95% confidence interval 0.47-0.73; p=0.000004).
  • In third- and later-line patients, Sone-Ve delivered median overall survival of 10.0 months, versus 5.0 months. This dual primary endpoint recorded a hazard ratio of 0.47.
  • Progression-free survival in the overall population, the other dual primary endpoint and assessed by blinded independent central review, did not reach statistical significance (p=0.053193).
  • Grade 3 or higher treatment-related adverse events occurred in 36.4% of Sone-Ve patients and 44.8% of the comparator arm. The trial identified no new safety signals.

Overall survival supplied the filing’s efficacy case. The non-significant centrally reviewed progression-free survival result gives the FDA a specific counterweight, while the adverse-event comparison and absence of new safety signals provide context for its safety assessment.

Product and development scope

Sone-Ve is an investigational antibody-drug conjugate comprising an anti-CLDN18.2 monoclonal antibody, a protease-degradable linker and a cytotoxic MMAE payload. It holds Orphan Drug Designation from the FDA and European Commission for gastric and GEJ cancers, and Breakthrough Designation in China for second-line gastric cancer.

Applications based on CLARITY-Gastric01 also face review in the European Union, China and several other countries.

AstraZeneca plans to use the trial’s efficacy analyses to evaluate the Ventana SP455 assay for identifying patients whose tumours express CLDN18.2 and who may benefit from Sone-Ve. The Phase III CLARITY-Gastric02 trial tests Sone-Ve with capecitabine, with or without rilvegostomig, as a first-line treatment. Phase II studies cover CLDN18.2-positive pancreatic and biliary tract cancers.

Licence economics and ownership

AstraZeneca holds exclusive global rights to research, develop, manufacture and commercialise Sone-Ve through a licence completed with KYM Biosciences on 30 March 2023, when the medicine carried the name CMG901.

The agreement provided for a US$63 million upfront payment, potential development and sales-related milestone payments of up to $1.1 billion, and tiered royalties up to low double digits. KYM was established as a joint venture by affiliates of Keymed Biosciences and Lepu Biopharma.

The central regulatory question for the anticipated second-quarter 2027 decision is how the FDA weighs the survival data and broad biomarker threshold against the non-significant centrally reviewed progression-free survival result and the reported safety profile. Parallel regional reviews, diagnostic development and earlier-line trials will shape the KYM-licensed medicine’s wider regulatory and commercial reach.

For portfolio teams, the immediate milestone is the Q2 2027 FDA action, while broader reach depends on the parallel reviews, diagnostic work and earlier-line programme.

via FDA industry wire (Google News) (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

22 articles

Linked filings

  1. P-6323
  2. C-4460
  3. K-4971
  4. C-7166
  5. P-9899

« Previous filingNext filing »